COVID-19 vaccines

Dynavax to Report Second Quarter 2021 Financial Results and Host Conference Call on August 4, 2021

Retrieved on: 
Wednesday, July 21, 2021
Economy of New York City, NASDAQ, Conference call, Emeryville, California, Finance, Geography of California, COVID-19 vaccines, Clinical trials, Cities in the United States

EMERYVILLE, Calif., July 21, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2021 financial results on Wednesday, August 4, 2021, after the U.S. financial markets close.

Key Points: 
  • EMERYVILLE, Calif., July 21, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2021 financial results on Wednesday, August 4, 2021, after the U.S. financial markets close.
  • Dynavax will host a conference call and live audio webcast on Wednesday, August 4, 2021 at 4:30 p.m. (ET)/1:30 p.m. (PT).
  • The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations .
  • Alternatively, participants may dial (866) 420-4066 (domestic) or (409) 217-8237 (international) and refer to conference ID9970706.

Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial

Retrieved on: 
Wednesday, July 21, 2021
COVID-19 vaccines, Clinical trials, Vaccines, Medicine, Health sciences, RNA vaccines, Medical research, COVID-19 vaccine, Vaccine, Zhongyianke Biotech–Liaoning Maokangyuan Biotech COVID-19 vaccine, Herpes simplex research

Oravax is gearing up to commence clinical trials for its oral COVID-19 vaccine, first in Israel, then in additional clinical sites internationally.

Key Points: 
  • Oravax is gearing up to commence clinical trials for its oral COVID-19 vaccine, first in Israel, then in additional clinical sites internationally.
  • The oral VLP COVID-19 vaccine is being developed for use both as a standalone vaccine as well as a booster for people who have been previously vaccinated for COVID-19.
  • Oravax combines cutting-edge vaccine technology acquired from Premas Biotech and the proprietary POD oral delivery technology of Oramed Pharmaceuticals.
  • Established in 2006, with offices inthe United StatesandIsrael, Oramed has developed a novel Protein Oral Delivery (POD) technology.

Catalent Plans Multi-Phase, $100 Million Expansion of Italian Facility to Increase Biologics Manufacturing Capabilities in Europe

Retrieved on: 
Wednesday, July 21, 2021
COVID-19 vaccines, Clinical trials, RNA vaccines, Medicine, Life sciences, Health sciences, Catalent, Gene therapy, Medical research, Moderna COVID-19 vaccine, COVID-19 vaccine, Vaccine

SOMERSET, N.J., July 21, 2021 /PRNewswire-PRWeb/ -- Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply.

Key Points: 
  • The initial expansion is expected to be commissioned and operational for customer projects in April 2023 and will increase the site's workforce by up to 100 employees.
  • Later phases of the planned expansion contemplate the provision of 16,000 liters of total flexible manufacturing capacity, enabling 2,000-liter to 8,000-liter batch production scale.
  • Catalent's Anagni site is a world-class biologics and oral dose manufacturing facility that specializes in late-stage and commercial product launches.
  • Since Catalent acquired the facility, in January 2020, it has become a major European hub for COVID-19 vaccine manufacturing.

Expert Available to Comment on Potential COVID-19 Booster Shots, Global Vaccination Efforts

Retrieved on: 
Tuesday, July 20, 2021
Medicine, Health sciences, COVID-19 vaccines, COVID-19, Clinical trials, Medical research, Vaccines, COVID-19 vaccine, Vaccine, Vaccination, COVID-19 vaccination in the Philippines, Deployment of COVID-19 vaccines

Vaccine makers have announced plans to seek authorization for supplementary doses, yet many countries around the world still do not have vaccines available for all and their populations are at a greater risk of infection and disease.

Key Points: 
  • Vaccine makers have announced plans to seek authorization for supplementary doses, yet many countries around the world still do not have vaccines available for all and their populations are at a greater risk of infection and disease.
  • Dr. Reithinger has participated in several media interviews throughout the COVID-19 pandemic to provide insight on global vaccine distribution planning and vaccine diplomacy.
  • He can speak to the benefits and risks of prioritizing a third dose of the COVID-19 vaccine in the US vs. ramping up vaccination efforts in other countries across the globe.
  • Dr. Reithinger can also comment on the importance of working together with low-and-middle-income countries to rollout COVID-19 vaccines, while simultaneously prioritizing programs to eliminate other diseases.

Zogby Focus Groups Challenge Misconceptions About Relations Between Vaccinated and Unvaccinated

Retrieved on: 
Tuesday, July 20, 2021
Medicine, Virology, Medical specialties, COVID-19 vaccine, Medical research, Health sciences, Vaccine, COVID-19 vaccines, Clinical trials, Vaccine hesitancy, COVID-19 vaccination in Sweden

One focus group included adults who have not received the COVID-19 vaccine, while the other was made up of adults who received the COVID-19 shots.

Key Points: 
  • One focus group included adults who have not received the COVID-19 vaccine, while the other was made up of adults who received the COVID-19 shots.
  • While the unvaccinated participants appear largely unmovable regarding taking the COVID-19 vaccine, many in the group see the benefits of other vaccines.
  • Participants in both groups believed that pharmaceutical companies should be held accountable for injuries and deaths from vaccines.
  • These in-depth and balanced focus groups revealed so much grey area in what is often portrayed as a black and white, highly contentious debate between vaccinated and unvaccinated groups, said CHD Executive Director Laura Bono.

Free Digital COVID-19 Vaccine Card Service Now Available for Talbot County Residents

Retrieved on: 
Tuesday, July 20, 2021
COVID-19 vaccines, Clinical trials, RNA vaccines, Medical specialties, Medicine, COVID-19, COVID-19 vaccine card, Pfizer–BioNTech COVID-19 vaccine, Health, Vaccine, Moderna COVID-19 vaccine

EASTON, Md., July 20, 2021 /PRNewswire/ -- TalbotCounty Health Department and PinPoint US, LLC are partnering to offer free digital COVID-19 vaccine cards forTalbotCounty residents.

Key Points: 
  • EASTON, Md., July 20, 2021 /PRNewswire/ -- TalbotCounty Health Department and PinPoint US, LLC are partnering to offer free digital COVID-19 vaccine cards forTalbotCounty residents.
  • TheVaccineCheckservice will generate a personalized digital version of a CDC vaccine card after verifying COVID-19 vaccine history through Maryland's statewide immunization registry.
  • Residents can also use the service to upload images of their paper CDC vaccine card for safe digital record-keeping accessible through their smartphone or computer.
  • Many residents live and work in different jurisdictions, so we are pleased to offer this vaccine verification service across state and county lines," says Chris Nickerson, VaccineCheck Managing Partner.

Moderna Partners with Takeda and the Government of Japan to Supply Additional 50 Million Doses of Moderna’s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022

Retrieved on: 
Tuesday, July 20, 2021
Health, Infectious diseases, Genetics, Other Health, Pharmaceutical, Biotechnology, COVID-19 vaccines, Clinical trials, Medicine, Medical research, Health sciences, RNA vaccines, Health, BioNTech, Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine, COVID-19 vaccine, Moderna

This new supply agreement is in addition to the prior agreement for 50 million doses in 2021 resulting in a total of 100 million doses for Japan.

Key Points: 
  • This new supply agreement is in addition to the prior agreement for 50 million doses in 2021 resulting in a total of 100 million doses for Japan.
  • Moderna is responsible for the manufacture and supply of Modernas vaccine candidate, and Takeda, with the support of the MHLW and Moderna, is responsible for all import, local regulatory, development and distribution activities in Japan for these additional 50 million doses beginning in 2022.
  • We thank the MHLW and Takeda for their support and for partnering with us to bring our mRNA COVID-19 vaccine to Japan, said Stphane Bancel, Modernas Chief Executive Officer.
  • We remain committed to making our vaccine available around the world as we seek to address the pandemic.

Meissa Announces Preclinical Data on Intranasal COVID-19 Vaccine Showing Protection from SARS-CoV-2 Challenge after a Single Dose

Retrieved on: 
Tuesday, July 20, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Clinical trials, Clinical trials, COVID-19 vaccines, Coronaviridae, RNA vaccines, Medicine, Health sciences, COVID-19 vaccine, Medical research, Severe acute respiratory syndrome coronavirus, Rapid Deployment Vaccine Collaborative, ZF2001

The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2 challenge compared to reported efficacy in NHP models of currently authorized vaccines.

Key Points: 
  • The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2 challenge compared to reported efficacy in NHP models of currently authorized vaccines.
  • The data suggest a single, adjuvant-free, needle-free intranasal dose of MV-014-212 may provide broad immunity to protect against infection by SARS-CoV-2 and its variants.
  • In NHPs, Meissas intranasal COVID-19 vaccine generated both mucosal and systemic antibodies and was highly protective against wild-type SARS-CoV-2 challenge.
  • We believe Meissas intranasal COVID-19 vaccine has the potential to be an important part of the endgame solution to contain SARS-CoV-2.

Todos Medical to Launch EUA Authorized cPass SARS-CoV-2 Neutralizing Antibody Kit Through Agreement with Fosun Pharma

Retrieved on: 
Monday, July 19, 2021
Medical specialties, Branches of biology, Medicine, Antibodies, Neutralizing antibody, Viral diseases, Development of COVID-19 tests, COVID-19 vaccines, DiaSorin

The Company is currently automating the EUA cPass test at itsCLIA/CAP laboratory, Provista Diagnostics (Provista), to add high-capacity neutralizing antibody testing to its test menu, and is ramping up its sales and marketing infrastructure.

Key Points: 
  • The Company is currently automating the EUA cPass test at itsCLIA/CAP laboratory, Provista Diagnostics (Provista), to add high-capacity neutralizing antibody testing to its test menu, and is ramping up its sales and marketing infrastructure.
  • Todos will also make cPass available for client labs to run on their automated equipment.
  • This test has been authorized by FDA under an EUA for use by authorized laboratories.
  • This test has been authorized only for the presence of total neutralizing antibodies against SARS-CoV-2, not for any other viruses or pathogens.

SVMHS Helps Vaccinate Indigenous Population

Retrieved on: 
Friday, July 16, 2021
COVID-19 vaccines, Clinical trials, RNA vaccines, Medical research, BioNTech, Medicine, Health sciences, Articles, Pfizer–BioNTech COVID-19 vaccine, COVID-19 vaccine, COVID-19 vaccination in Canada

In June, SVMHS partnered with Centro Binacional para el Desarollo Indigena Oaxaqueno (CBDIO) to deliver free COVID-19 vaccine to underserved populations.

Key Points: 
  • In June, SVMHS partnered with Centro Binacional para el Desarollo Indigena Oaxaqueno (CBDIO) to deliver free COVID-19 vaccine to underserved populations.
  • The Center identified Greenfield as a vulnerable community needing easy access to the vaccine and the convenience of the SVMHS Mobile Health Clinic.
  • Our partnerships with grass roots organizations serving indigenous populations are more important than ever before."
  • SVMHS Mobile Health Clinic staff deliver COVID-19 Pfizer first doses to Greenfield residents at a special vaccine clinic on June 26.